Navigation Links
Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
Date:9/15/2008

gets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The fourth clinical stage antibody is MT293 which is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. Three additional BiTE antibodies, targeting CD33, CEA and MCSP, respectively, are in preclinical development. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of our product candidates, the development of our BiTE antibody technology, the conduct, timing and results of future clinical trials, expectations of the future expansion of our product pipeline and collaborations, and our plans regarding future presentations of clinical data. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expresse
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
2. Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results
3. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
4. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
5. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
6. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
7. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
8. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
9. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
10. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
11. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Aug. 4, 2015  ContraVir Pharmaceuticals, Inc. (NASDAQ: ... the development and commercialization of targeted antiviral therapies, ... Officer, will present live at VirtualInvestorConferences.com on August ... 2015 TIME: 12:15PM EDT LINK: http://tinyurl.com/aug6-pre-ctrv ... interactive online event where investors are invited to ...
(Date:8/4/2015)... 4, 2015  Syneron Medical Ltd. (NASDAQ: ELOS ), ... for the three month period ended June 30, 2015. ... 1 Highlights: , Revenue of $73.5 ... , North American product sales grew 45% year-over-year. , ... including 14% product growth in the EMEA region and 25% ...
(Date:8/3/2015)... -- Landauer, Inc. (NYSE: LDR ), a recognized leader ... medical physics services and high quality medical consumable accessories, ... fiscal third quarter 2015 after the market close on ... will also host a conference call for investors on ... (10:00 a.m. Eastern Time). Investors may access the live ...
Breaking Medicine Technology:ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 3Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 2Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 3Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 4Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 5Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 6Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 7Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 8Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 9Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 10Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 11Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 12Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 13Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 14Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 15Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 16Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 17Landauer, Inc. Announces Date And Time For Announcement Of Fiscal Third Quarter 2015 Results And Conference Call 2
... (NASDAQ: VOLC ), a leading developer and ... designed to enhance the treatment of coronary and peripheral ... in the Bank of America Merrill Lynch Health Care ... by Scott Huennekens, president and chief executive officer, will ...
... Mass., May 4, 2011 NxStage Medical, Inc. (Nasdaq: ... dialysis products, today announced that it has received regulatory ... NxStage System One™ and signed a five-year agreement, the ... Care Group (RHCG), a leading distributor of medical products ...
Cached Medicine Technology:NxStage® Advances Global Growth Strategy with System One™ Regulatory Approval and Distribution Agreement in Australia and New Zealand 2NxStage® Advances Global Growth Strategy with System One™ Regulatory Approval and Distribution Agreement in Australia and New Zealand 3
(Date:8/4/2015)... York, New York (PRWEB) , ... August 04, 2015 , ... ... this doesn’t begin to describe the customer experience inside Naimie’s Beauty Center in LA. ... help men learn how to look better. , Naimie’s Beauty Center has been a ...
(Date:8/4/2015)... ... August 04, 2015 , ... MedicaSoft ... Office of the National Coordinator for Health Information Technology (ONC-HIT) 2014 Edition ... highest quality personal health record and patient portal solution to healthcare providers ...
(Date:8/4/2015)... ... August 04, 2015 , ... Armadale ... finance, announced the closing of a $118 million FHA-insured loan modification refinancing for ... in Smithfield and Clayton, North Carolina. JHSC is a joint venture of ...
(Date:8/4/2015)... ... 04, 2015 , ... Half of consumers are considering a ... increasingly influential in their choice of practitioner, according to new survey data from ... Cosmetic Dermatologic Procedures reflects overall consumer views on cosmetic medical treatments and ratings ...
(Date:8/4/2015)... ... August 04, 2015 , ... Mercy Health (formerly Catholic Health Partners) – a Catholic ... Health: Helping You Be Well videos to preparing high school athletes for fall sports. , ... addresses issues, such as:, , What steps to take to help ...
Breaking Medicine News(10 mins):Health News:MENAJI Shines in Make-Up Mecca for Stars 2Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 2Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 3Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 2Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 3Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 2Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 3Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 4Health News:Mercy Health Video Provides Helpful Information for High School Athletes 2
... Preserving Choice, SACRAMENTO, Calif., Dec. 26 ... non-government HIV testing,program in California, today offered its ... into law yesterday in New Jersey by Acting ... testing of pregnant,women and some newborns for HIV, ...
... Inhibiting the growth of blood vessels that supply ... according to results of a large clinical trial ... in the December 27th issue of the New ... combination with chemotherapy significantly prolongs progression-free survival for ...
... to halting of cancer therapy, report says , , WEDNESDAY, ... for prostate cancer who take baby aspirin to protect ... new research suggests. , Apparently, baby aspirin interacts with ... end result is the man must stop potentially lifesaving ...
... Gentiva Health,Services, Inc. (Nasdaq: GTIV ), the ... announced today that it is,scheduled to present from 1:30 ... the 26th Annual JPMorgan Healthcare Conference in San Francisco., ... via a live audio web cast,which may be accessed ...
... taken more seriously , , WEDNESDAY, Dec. 26 (HealthDay News) ... person,s risk of having a stroke or developing dementia, ... to previous research linking "mini-strokes" to full-fledged strokes, make ... neurology at Johns Hopkins University School of Medicine. , ...
... feature new commercials, print ads and a new website, ... ) today announced that the Company will unveil a new ... 2008. The,focus of the campaign will be celebrity spokeswoman Genie ... just a few months on the,Medifast Program. Francis is best ...
Cached Medicine News:Health News:AHF Says 'Op-Out' Clause is Crucial to New Jersey Law Requiring HIV Testing of Pregnant Women 2Health News:AHF Says 'Op-Out' Clause is Crucial to New Jersey Law Requiring HIV Testing of Pregnant Women 3Health News:Bevacizumab found to improve survival for patients with advanced breast cancer 2Health News:Aspirin, Hormone Therapy Combo Can Shorten Lives of Prostate Cancer Patients 2Health News:Aspirin, Hormone Therapy Combo Can Shorten Lives of Prostate Cancer Patients 3Health News:Gentiva(R) Health Services to Present January 8 at JPMorgan Healthcare Conference in San Francisco 2Health News:Gentiva(R) Health Services to Present January 8 at JPMorgan Healthcare Conference in San Francisco 3Health News:Temporary Amnesia, Confusion Raise Stroke, Dementia Risk 2Health News:Temporary Amnesia, Confusion Raise Stroke, Dementia Risk 3Health News:Medifast, Inc. to Unveil New Advertising Campaign Featuring Genie Francis and New Web Features in Early 2008 2Health News:Medifast, Inc. to Unveil New Advertising Campaign Featuring Genie Francis and New Web Features in Early 2008 3Health News:Medifast, Inc. to Unveil New Advertising Campaign Featuring Genie Francis and New Web Features in Early 2008 4
... of insulin is the C-terminal cleavage product ... to the mature insulin molecule. Although the ... does undergo significant liver or extra-renal metabolism ... half-life than insulin [1]. In addition, C-peptide ...
... a 32 kDa glycoprotein secreted by the ... [1]. The structure of human TSH is ... placental gonadotropins, consisting of an a-subunit which ... and a unique beta-subunit, which confers hormonal ...
... primarily by 5-monodeioination of thyroxine (T4) in ... production occurs at a rate which is ... of T3 from the thyroid gland into ... to 80-100 micrograms/day for T4. In addition, ...
... monomeric protein produced and stored in somatotrophs ... released from the pituitary into the bloodstream ... control of hypothalamic somatostatin (SS) and GH-releasing ... of GH release appears to be regulated ...
Medicine Products: